The Oncosearch | Oncotarget

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts Research Paper

Jesus Delgado-Calle, Noriyoshi Kurihara, Emily G. Atkinson, Jessica Nelson, Kazuaki Miyagawa, Carlos Maria Galmarini, G. David Roodman, Teresita Bellido

Published Apr 12, 2019 · Vol. 10, No. 28 · pp. 2709-2721

Keywords: myeloma, osteoclasts, osteocytes, osteoblasts, tumor

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma Research Paper

Chuang Sun, Aruna Mahendravada, Brandon Ballard, Brandon Kale, Carlos Ramos, John West, Todd Maguire, Katie McKay, Eben Lichtman, Sascha Tuchman, Gianpietro Dotti, Barbara Savoldo

Published Mar 22, 2019 · Vol. 10, No. 24 · pp. 2369-2383

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-Î³ Research Paper

Masami Iwasa, Takeshi Harada, Asuka Oda, Ariunzaya Bat-Erdene, Jumpei Teramachi, Hirofumi Tenshin, Mohannad Ashtar, Masahiro Oura, Kimiko Sogabe, Kengo Udaka, Shiro Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Masahiro Abe

Published Mar 8, 2019 · Vol. 10, No. 20 · pp. 1903-1917

N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma Research Paper

Yoshiaki Abe, Tetsuya Kobayashi, Yoshiaki Usui, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Daisuke Miura, Masami Takeuchi, Kosei Matsue

Published Feb 1, 2019 · Vol. 10, No. 10 · pp. 1160-1170

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53 Research Paper

Cody Ashby, Ruslana G. Tytarenko, Yan Wang, Niels Weinhold, Sarah K. Johnson, Michael Bauer, Christopher P. Wardell, Carolina Schinke, Sharmilan Thanendrarajan, Mauricio Zangari, Frits van Rhee, Faith E. Davies, Jeffrey R. Sawyer, Gareth J. Morgan, Brian A. Walker

Published Jan 22, 2019 · Vol. 10, No. 7 · pp. 732-737

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society Research Paper

Yoshiaki Abe, Kazutaka Sunami, Takeshi Yamashita, Mikio Ueda, Hiroyuki Takamatsu, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue

Published Jan 15, 2019 · Vol. 10, No. 5 · pp. 595-605

Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001 Research Paper

Cristina L. Abrahams, Xiaofan Li, Millicent Embry, Abigail Yu, Stellanie Krimm, Sarah Krueger, Nancy Y. Greenland, Kwun Wah Wen, Chris Jones, Venita DeAlmeida, Willy A. Solis, Shannon Matheny, Toni Kline, Alice Y. Yam, Ryan Stafford, Arun P. Wiita, Trevor Hallam, Mark Lupher, Arturo Molina

Published Dec 28, 2018 · Vol. 9, No. 102 · pp. 37700-37714

PRMT5 inhibitors on the (myeloma) road Editorial

Annamaria Gulla, Teru Hideshima, Kenneth C. Anderson

Published Nov 19, 2018 · Vol. 9, No. 94 · pp. 36646-36647

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy Correction

Toril Holien, Kristine Misund, Oddrun Elise Olsen, Katarzyna Anna Baranowska, Glenn Buene, Magne BÃ¸rset, Anders Waage, Anders Sundan

Published Nov 13, 2018 · Vol. 9, No. 89 · pp. 36048-36048

Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution Research Paper

Joshua N. Kellner, Eveline M. Delemarre, Eric Yvon, Stefan Nierkens, Jaap J. Boelens, Ian McNiece, Amanda Olson, Yago Nieto, Stefan Ciurea, Uday Popat, Sairah Ahmed, Richard Champlin, Jennifer Ramos, Mitsutaka Nishimoto, Hongbing Ma, Zeng Ke, Peter Thall, Joseph D. Khoury, Robert Negrin, Borje Andersson, Simrit Parmar

Published Nov 2, 2018 · Vol. 9, No. 86 · pp. 35611-35622

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma Editorial

Phuc H. Hoang, Richard S. Houlston

Published Oct 30, 2018 · Vol. 9, No. 88 · pp. 35801-35802

IMiDs for myeloma induced renal impairment Editorial

Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos

Published Oct 18, 2018 · Vol. 9, No. 84 · pp. 35476-35477

The genomic features associated with high-risk multiple myeloma Editorial

Brian A. Walker, Gareth J. Morgan

Published Oct 18, 2018 · Vol. 9, No. 84 · pp. 35478-35479

Clinical impact of serum soluble SLAMF7 in multiple myeloma Research Paper

Mariko Ishibashi, Saori Soeda, Makoto Sasaki, Hiroshi Handa, Yoichi Imai, Norina Tanaka, Sakae Tanosaki, Shigeki Ito, Takeshi Odajima, Hiroki Sugimori, Toshio Asayama, Mika Sunakawa, Yuta Kaito, Ryosuke Kinoshita, Yasuko Kuribayashi, Asaka Onodera, Keiichi Moriya, Junji Tanaka, Yutaka Tsukune, Norio Komatsu, Koiti Inokuchi, Hideto Tamura

Published Oct 5, 2018 · Vol. 9, No. 78 · pp. 34784-34793

Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma Research Paper

Utkarsh Painuly, Vijay Ramakrishnan, Teresa Kimlinger, Linda Wellik, Jessica Haug, Wilson Gonsalves, Lintao Bi, Zhongxia Huang, S. Vincent Rajkumar, Shaji Kumar

Published Oct 2, 2018 · Vol. 9, No. 77 · pp. 34582-34594

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients Research Paper

Laurens E. Franssen, Inger S. Nijhof, Chad C. Bjorklund, Hsiling Chiu, Ruud Doorn, Jeroen van Velzen, Maarten Emmelot, Berris van Kessel, Mark-David Levin, Gerard M.J. Bos, Annemiek Broijl, Saskia K. Klein, Harry R. Koene, Andries C. Bloem, Aart Beeker, Laura M. Faber, Ellen van der Spek, Reinier Raymakers, Pieter Sonneveld, Sonja Zweegman, Henk M. Lokhorst, Anjan Thakurta, Xiaozhong Qian, Tuna Mutis, Niels W.C.J. van de Donk

Published Sep 21, 2018 · Vol. 9, No. 74 · pp. 34009-34021

Ex vivo generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigen Research Paper

Joshua N. Kellner, Eric Yvon, Simrit Parmar

Published Sep 14, 2018 · Vol. 9, No. 72 · pp. 33694-33701

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma Editorial

Jakub Krejcik, Niels W.C.J. van de Donk

Published Aug 31, 2018 · Vol. 9, No. 72 · pp. 33621-33622

PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients Research Paper

Anne-Marit Sponaas, Rui Yang, Even Holth Rustad, Therese Standal, Aud Solvang Thoresen, Camilla Dao Vo, Anders Waage, Tobias S. SlÃ¸rdahl, Magne BÃ¸rset, Anders Sundan

Published Aug 10, 2018 · Vol. 9, No. 62 · pp. 32024-32035

STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models Research Paper

Gabriela Rozic, Lena Paukov, Ziv Cohen, Irit Shapira, Adrian Duek, Ohad Bejamini, Abraham Avigdor, Arnon Nagler, Igor Koman, Merav Leiba

Published Jul 31, 2018 · Vol. 9, No. 59 · pp. 31367-31379

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts Research Paper

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma Research Paper

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-Î³ Research Paper

N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma Research Paper

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53 Research Paper

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society Research Paper

Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001 Research Paper

PRMT5 inhibitors on the (myeloma) road Editorial

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy Correction

Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution Research Paper

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma Editorial

IMiDs for myeloma induced renal impairment Editorial

The genomic features associated with high-risk multiple myeloma Editorial

Clinical impact of serum soluble SLAMF7 in multiple myeloma Research Paper

Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma Research Paper

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients Research Paper

Ex vivo generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigen Research Paper

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma Editorial

PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients Research Paper

STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts Research Paper

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma Research Paper

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-Î³ Research Paper

N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma Research Paper

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53 Research Paper

Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society Research Paper

Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001 Research Paper

PRMT5 inhibitors on the (myeloma) road Editorial

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy Correction

Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution Research Paper

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma Editorial

IMiDs for myeloma induced renal impairment Editorial

The genomic features associated with high-risk multiple myeloma Editorial

Clinical impact of serum soluble SLAMF7 in multiple myeloma Research Paper

Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma Research Paper

Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients Research Paper

Ex vivo generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigen Research Paper

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma Editorial

PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients Research Paper

STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models Research Paper